Master Protocols Explained: Basket, Umbrella, and Platform Trials
Imagine a clinical trial that is not a single experiment but a perpetual testing engine. A trial that can add new treatments as they become available, drop ineffective ones early, and answer dozens of research questions at the same time using shared infrastructure. That is the vision of master protocols, and it is one of the most important innovations in clinical trial design in decades. The Clarity Clinical Solutions video on master protocols explains the three main types: basket trials, umbrella trials, and platform trials.
What a master protocol is
A master protocol is an overarching structure: a single protocol that governs multiple sub-studies, each potentially testing different treatments or patient populations. Instead of running a separate trial for every drug and disease combination, with its own protocol, its own ethics committee review, its own site contracts, and its own data management system, a master protocol shares all of that infrastructure. One protocol, one institutional review board, one data system, one network of clinical sites. New treatment arms can be added in weeks instead of years.
Basket trials
A basket trial enrolls patients with different disease types, say breast cancer, lung cancer, and colorectal cancer, that all share a specific genetic mutation, and gives them all the same targeted drug. The question is whether the drug works in any cancer carrying that mutation, regardless of where the tumor originated.
Basket trials are built on the idea that genetic mutations in cancer can matter more than where the cancer started. For example, a drug targeting the BRAF V600E mutation might work in melanoma, colorectal cancer, lung cancer, and thyroid cancer, all of which can carry that mutation. Rather than running four separate trials, a basket trial enrolls all eligible patients under one protocol and analyzes response rates in each disease-specific basket.
The most ambitious example is NCI-MATCH, which screened thousands of patients and tested dozens of targeted therapy arms across hundreds of tumor types. Basket trials also led to the first tumor-agnostic drug approvals by the FDA, drugs approved for any solid tumor with a specific biomarker, regardless of where the cancer started.
Umbrella trials
An umbrella trial flips the basket concept around. Every patient has the same type of cancer, but they are assigned to different treatment arms based on the specific mutations found in their tumor. The classic example is I-SPY 2, a breast cancer platform that has tested dozens of experimental drugs since 2010. Patients are screened for a panel of biomarkers and assigned to the most appropriate experimental arm.
I-SPY 2 uses adaptive randomization, meaning that as data accumulates, more patients are assigned to the arms showing better results and fewer to the arms that look less promising. This is more ethical than traditional fixed randomization, because fewer patients are exposed to treatments that are not working, and it answers the research question faster.
Platform trials
Platform trials take the master protocol concept to its logical conclusion. They are designed to be open-ended. Treatments can enter the trial when they become available and leave when results are conclusive. All arms share a single control group.
The definitive example is the RECOVERY trial, launched in the UK in April 2020 during the first wave of COVID-19. It enrolled tens of thousands of patients across more than 180 UK hospitals and tested more than ten treatments, including dexamethasone, hydroxychloroquine, remdesivir, convalescent plasma, and tocilizumab, in about 18 months. The dexamethasone result alone, showing a large reduction in mortality for ventilated patients, became standard of care globally within weeks. The hydroxychloroquine arm enrolled thousands of patients before being stopped for futility, definitively answering whether that widely promoted drug worked. The whole trial cost a fraction of what a single pharmaceutical company would spend on a typical phase 3 trial.
Why regulators support them
The FDA has been increasingly supportive of master protocols. It issued draft guidance in 2018 and final guidance in 2022 covering trial design, statistical considerations, and regulatory expectations (FDA: Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics). The guidance emphasizes that each treatment arm within a master protocol must still meet the evidence standards for drug approval. The master protocol does not relax the evidence requirements.
The statistical and operational challenges
Master protocols require sophisticated statistical methods. Adaptive randomization changes the probability of assigning patients to each arm based on accumulating results, so more patients go to better-performing arms. Bayesian methods borrow information across treatment arms, improving precision for smaller subgroups. And because multiple treatments are tested at the same time, careful control of false positives is essential. Methods like gatekeeping procedures and Bayesian multiplicity adjustments keep the overall error rate acceptable while maximizing efficiency.
Operationally, the challenges are equally significant. Governance: who decides when to add or drop a treatment arm? Sponsorship: which company holds the investigational new drug application for the master protocol? Data rights: how do competing pharmaceutical companies share control-group data? Drug supply: coordinating shipments from multiple manufacturers is complex. And sustainable funding for long-running platform trials remains a persistent problem.
When master protocols make sense
Master protocols are not for every research question. The statistical complexity is substantial, and the operational overhead of coordinating multiple sponsors, drug manufacturers, and regulatory submissions can be overwhelming. They work best when there is a strong biological rationale for biomarker-driven treatment, when multiple experimental treatments are ready for testing, when a shared control arm is appropriate, and when the research community is willing to collaborate. For simple questions, does this drug work for this condition compared with placebo, a traditional randomized trial is often the better choice.
Looking ahead, master protocols are expanding beyond oncology. Platform trials for Alzheimer's disease, autoimmune conditions, and cardiovascular prevention are being developed, and the infrastructure created for RECOVERY is being maintained as a permanent pandemic response platform. In the longer term, master protocols could support learning health care systems where clinical research is continuously integrated with patient care.
The bottom line
Master protocols do not replace traditional randomized controlled trials, but they add a powerful option when multiple questions need answering efficiently: multiple promising treatments, identifiable patient subgroups, and a research community ready to collaborate. By sharing infrastructure, controlling costs, and adapting to emerging data, these designs accelerate the pace of clinical discovery. They have already changed practice through trials like RECOVERY, and as they expand beyond oncology, they will become an increasingly common tool in the clinical researcher's toolbox.
This article is based on the Clarity Clinical Solutions video "Master Protocols Basket Umbrella | Clinical Research Explained." Watch it here: Master Protocols Basket Umbrella | Clinical Research Explained
References
- Clarity Clinical Solutions — Master Protocols Basket Umbrella | Clinical Research Explained (video). https://www.youtube.com/watch?v=g-xf8yOFL3c
- FDA — Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics (guidance). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and
- RECOVERY Trial — The platform trial that tested multiple COVID-19 treatments across UK hospitals. https://www.recoverytrial.net/
- National Cancer Institute — NCI-MATCH, the basket trial screening thousands of patients for targeted therapy arms. https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match
- ClinicalTrials.gov — Main search portal for registered trials, including master protocol studies. https://clinicaltrials.gov/